Epigenomics · 2018 · 139 citations · 14 references
MedicineBioinformaticsOncologyChemotherapyMolecular OncologyNeoplasiaCancer BiomarkersCancer TranscriptomicsExosome AnalysisMolecular Tumor ProfilingNext-generation Sequencing In OncologyNoncoding Rna In CancerClinicopathological CorrelationExosomal Microrna AnalysisExosomal Noncoding RnaExosomes In CancerMicrorna In CancerMicrorna Prognostic MarkersPredictive BiomarkersReal-time Polymerase Chain Reaction (Pcr)
AIM: To analyze the expression profiles, clinicopathological features and chemotherapeutic efficacies of exosome-derived miRNAs in diffuse large B-cell lymphoma (DLBCL). MATERIALS & METHODS: Next-generation sequencing technique was performed to identify miRNA profiles in exosomes from parental and chemoresistant DLBCL cells. The results were validated by quantitative real-time PCR, and further analyzed by bioinformatics and statistical methods. RESULTS: We identified 37 significantly upregulated and 17 downregulated miRNAs. Of four upregulated miRNAs validated, we found miR-99a-5p and miR-125b-5p were significantly upregulated. Increased levels of exosomal miR-99a-5p and miR-125b-5p in DLBCL patients' serum were associated with shorter progression-free survival time, and they can predict chemotherapeutic efficacy. CONCLUSION: Exosomal miR-99a-5p and miR-125b-5p can serve as biomarkers for DLBCL.
14
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Roland Schmitz, George W. Wright, Da Wei Huang et al. · New England Journal of Medicine · 2018 · 2.3K citations · Full text